Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corp director Myla Lai-Goldman reported new equity awards in the company’s common stock. On January 2, 2026, she received 23,372 restricted stock units that will vest in full on January 2, 2027 under Quanterix’s Amended and Restated Non-Employee Director Compensation Policy, with each unit representing one share of common stock. The same day, she was also granted 1,944 shares of common stock issued in lieu of cash fees for serving on the board and its committees for the fourth quarter of 2025. Both awards were recorded at a price of $0.00 per share. After these transactions, she directly beneficially owned 54,804 shares of Quanterix common stock, which the filing notes include 47,836 restricted stock units.
Quanterix Corp director Scott Mendel reported new equity awards in the company’s stock. On 01/02/2026, he received 23,372 restricted stock units that will vest in full on January 2, 2027 under the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy, with each unit representing one share of common stock. On the same date, he was also granted 1,944 shares of common stock issued in lieu of cash fees for his Board and committee service for the fourth quarter of 2025. Following these awards, he beneficially owned 56,053 shares of Quanterix common stock, including 47,836 restricted stock units, all reported as directly held.
Quanterix Corporation’s Chief Financial Officer reported a routine share adjustment related to equity compensation. On 12/15/2025, 229 shares of common stock were withheld by Quanterix at a price of $7.41 per share to cover tax obligations that arose when 777 restricted stock units (RSUs) vested. After this tax withholding, the officer beneficially owns 85,977 shares of Quanterix common stock, which includes 84,652 RSUs. This filing reflects administrative handling of taxes on vested stock awards rather than an open-market purchase or sale.
Quanterix Corp reported an insider equity transaction by its President & CEO and Director on 12/15/2025. The filing shows that 1,242 shares of common stock were withheld by Quanterix solely to cover tax obligations that arose when 3,722 restricted stock units (RSUs) vested. This is recorded as a disposition at a price of $7.41 per share for reporting purposes.
Following this tax withholding event, the reporting person beneficially owned 508,704 shares of Quanterix common stock, which includes 212,123 RSUs. The transaction was filed as a Form 4 for a single reporting person in their roles as both Director and President & CEO.
Quanterix Corp (QTRX) director files initial ownership report showing no holdings. A reporting person serving as a director of Quanterix Corporation has filed an initial Form 3 disclosing their beneficial ownership status as of 11/24/2025. The filing indicates that the director has no non-derivative securities beneficially held, with the amount reported as 0.00 shares held directly. The table for derivative securities is also blank, implying there are no options, warrants, or other derivative positions reported at this time. This is a routine disclosure required when an individual becomes an insider under U.S. securities rules.
Quanterix Corp (QTRX) reported a new equity award to one of its directors. On November 20, 2025, the director acquired 46,727 shares of common stock through a grant of restricted stock units (RSUs), reported as an acquisition in a Form 4 filing. Following this grant, the director beneficially owns 46,727 shares directly.
The RSUs vest in three equal installments. One-third of the total shares vest on each of November 20, 2026, November 20, 2027 and November 20, 2028, provided the director continues to provide service to Quanterix on each vesting date. This filing reflects routine director equity compensation rather than an open‑market purchase or sale.
Quanterix Corporation (QTRX) reported a new stock option grant to its Executive Chair and Director. On 11/20/2025, the insider acquired stock options to purchase 70,091 shares of Quanterix common stock at an exercise price of $5.91 per share. These options expire on 11/20/2035.
The options vest monthly over two years in 24 equal installments, as long as the Executive Chair continues providing service to Quanterix on each vesting date. Following this transaction, the reporting person beneficially owns 70,091 derivative securities directly.
Quanterix Corporation’s Chief Financial Officer reported a routine equity transaction on Form 4. On 11/15/2025, 229 shares of common stock were withheld by Quanterix solely to cover tax obligations when 777 restricted stock units vested. After this tax withholding, the reporting person beneficially owns 86,206 shares of Quanterix common stock, which includes 85,429 restricted stock units that may convert into shares over time.
Quanterix Corp (QTRX) reported an insider equity transaction by its President & CEO, who is also a director. On 11/15/2025, 1,242 shares of common stock were withheld under transaction code "F", meaning the shares were retained by the company solely to cover tax obligations triggered by the vesting of 2,480 restricted stock units (RSUs). Following this tax withholding, the reporting person beneficially owns 510,200 shares of Quanterix common stock, which includes 216,606 RSUs.
Quanterix Corporation reported changes to its Board of Directors. Long-time directors Paul Meister and David Walt, Ph.D. retired from the Board and all its committees, and their departures were stated as not arising from any disagreement with the company’s operations, policies, or practices.
The Board appointed Garret Hampton, Ph.D., as a Class II director with a term expiring at the 2028 annual meeting, and Alan Sachs, M.D., Ph.D., as a Class I director with a term expiring at the 2027 annual meeting. Dr. Hampton will serve on the Audit and Compensation Committees, while Dr. Sachs will serve on the Compensation Committee.
Both new directors will receive an annual cash retainer of $50,000 plus additional committee retainers. Each will receive an initial restricted stock unit grant equal to 0.1% of Quanterix’s outstanding common shares on the grant date, vesting over three years, and ongoing annual RSU grants equal to 0.05% of outstanding shares, vesting after one year.